Acadia Pharmaceuticals vs Amphstar Pharmaceuticals
Acadia Pharmaceuticals reported revenue of $1.1 billion in fiscal 2025, 1.5 times Amphstar Pharmaceuticals' $720 million in fiscal 2025. Acadia Pharmaceuticals' revenue grew 11.9% in its latest year, and Amphstar Pharmaceuticals' fell 1.6%. Acadia Pharmaceuticals had an operating margin of 9.8%, against 19.5% at Amphstar Pharmaceuticals. Free cash flow was $105 million at Acadia Pharmaceuticals and $121 million at Amphstar Pharmaceuticals.
Side by side
| Acadia Pharmaceuticals | Amphstar Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.1B | $720M |
| Revenue growth | 11.9% | −1.6% |
| Revenue growth a year, last 5 years | 19.4% | 15.5% |
| Gross margin | 91.7% | 49.5% |
| Operating margin | 9.8% | 19.5% |
| Net margin | 36.5% | 13.6% |
| Free cash flow | $105M | $121M |
| Free cash flow margin | 9.8% | 16.8% |
| Return on capital | — | 9.9% |
| Net debt to EBITDA | — | 1.7x |
| Dividends and buybacks | $0M | $76M |
| Change in diluted share count | 2.1% | −7.4% |
| Last close | $19.74 | $25.47 |
| P/E at the last close | 8.9× | 15.1× |
| Insider trades, last 12 months | sold $3.4 million | sold $1.7 million |
| Piotroski F-score | — | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Acadia PharmaceuticalsAmphstar Pharmaceuticals
Operating margin
Percent of revenue
Acadia PharmaceuticalsAmphstar Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Acadia PharmaceuticalsAmphstar Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Acadia Pharmaceuticals and Amphstar Pharmaceuticals pages.